No Data
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) said Tuesday that the US Food and Drug Administration has accepted its new-drug application for the combination therapy of vanzacaftor, tezacaftor, and deutivacaftor to t
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy
By Colin Kellaher Vertex Pharmaceuticals has won Food and Drug Administration priority review for its application seeking approval of a triple combination therapy for the genetic lung disease cystic
Express News | Vertex Pharmaceuticals Inc: EU Marketing Authorization Application (Maa) Submission Validated by EMA
Express News | Vertex Pharmaceuticals Inc: Vanza Triple Granted Priority Review With Prescription Drug User Fee Act (Pdufa) Target Action Date of January 2, 2025
Express News | Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
Vertex to Announce Second Quarter 2024 Financial Results on August 1
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast